{{Drugbox
| IUPAC_name = 5-(2-fluorophenyl)-3-hydroxy-7-nitro-2,3-dihydro-1''H''-1,4-benzodiazepin-2-one
| image = Nifoxipam.svg
| width = 222
| image2 = Nifoxipam ball-and-stick model.png
| width2 = 200

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_CA = Schedule IV
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 74723-10-7
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 3058221
| ChemSpiderID = 2319383
| UNII = 9O6C9M3CH6

<!--Chemical data-->
| C=15 | H=10 | F=1 | N=3 | O=4
| molecular_weight = 315.256 g/mol
| melting_point =
| smiles = O=C1C(O)N=C(C2=CC=CC=C2F)C3=CC([N+]([O-])=O)=CC=C3N1
| StdInChI = 1S/C15H10FN3O4/c16-11-4-2-1-3-9(11)13-10-7-8(19(22)23)5-6-12(10)17-14(20)15(21)18-13/h1-7,15,21H,(H,17,20)
| StdInChIKey = UHFIFTRHLBAWGY-UHFFFAOYSA-N
}}

'''Nifoxipam''' ('''3-hydroxydesmethylflunitrazepam''', '''DP 370''') is a [[benzodiazepine]] that is a minor [[metabolite]] of [[flunitrazepam]] and has been sold online as a [[designer drug]].<ref name="Kosselt_1985">{{cite web | url=https://www.google.com/patents/EP0158267A2 | title=Patent EP 0158267 A2 - Pharmaceutical composition containing 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro- or 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one and process for their preparation | date=16 October 1985 | accessdate=3 August 2015 | author=Klaus Posselt, Hans Heinrich Prof. Med. Wagener, Klaus Gruber}}</ref><ref>{{cite web | url=http://nsddb.eu/substance/478/ | title=Nifoxipam | publisher=New Synthetic Drugs Database}}</ref><ref>{{cite journal | url=http://dmd.aspetjournals.org/content/29/4/460.long | title=Flunitrazepam Metabolism by Cytochrome P450s 2C19 and 3A4 |author1=Tansel Kilicarslan |author2=Robert L. Haining |author3=Allan E. Rettie |author4=Usanda Busto |author5=Rachel F. Tyndale |author6=Edward M. Sellers | journal=Drug Metabolism and Disposition |date=April 2001  | volume=29 | issue=4 | pages=460–465 | pmid=11259331}}</ref><ref name="MoosmannKing2015">{{cite journal|last1=Moosmann|first1=Bjoern|last2=King|first2=Leslie A.|last3=Auwärter|first3=Volker|title=Designer benzodiazepines: A new challenge|journal=World Psychiatry|volume=14|issue=2|date=June 2015|pages=248|issn=1723-8617|doi=10.1002/wps.20236|pmid=26043347|pmc=4471986}}</ref><ref>{{cite web | url=http://www.kfx.org.uk/drug_facts/drug_facts_images_and_pdfs/researchchemicals_4.2015.pdf | title=Drug Facts - Newer Unregulated Drugs | publisher=KFx | date=August 2015 | accessdate=15 August 2015 | author=Kevin Flemen}}</ref><ref>{{cite web | url=http://www.wedinos.org/db/materials/view/00713 | title=Nifoxipam | publisher=WEDINOS}}</ref><ref>{{cite journal | author1=Markus R. Meyer | url=https://link.springer.com/article/10.1007/s00216-016-9439-6 | title=Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes | date=May 2016 | author2=Madeleine Pettersson Bergstrand | author3=Anders Helander | author4=Olof Beck | journal=Analytical and Bioanalytical Chemistry | volume=408 | issue=13 | pages=3571-3591 | doi=10.1007/s00216-016-9439-6 | pmid=27071765}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.2003/abstract | title=Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays |author1=Madeleine Pettersson Bergstrand |author2=Anders Helander |author3=Therese Hansson |author4=Olof Beck | journal=Drug Testing and Analysis | date=2016 | doi=10.1002/dta.2003 | pmid=27366870}}</ref><ref>{{cite journal|first1=Maria|last1=Katselou|first2=Ioannis|last2=Papoutsis|first3=Panagiota|last3=Nikolaou|first4=Chara|last4=Spiliopoulou|title=Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam|url=https://link.springer.com/article/10.1007/s11419-016-0338-5|journal=Forensic Toxicology|date=2016|issn=1860-8973|doi=10.1007/s11419-016-0338-5|first5=Sotiris|last5=Athanaselis}}</ref>

Nifoxipam produces strong tranquillising and sleep-prolonging effects and has much lower toxicity compared to [[lormetazepam]] and flunitrazepam in mice.<ref name="Kosselt_1985"/>

==See also==
* [[List of benzodiazepine designer drugs]]
* [[Nitrazolam]]
* [[Phenazepam]]

==References==
{{reflist}}

{{Benzodiazepines}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}
{{Glycinergics}}

[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Glycine receptor antagonists]]
[[Category:Lactams]]
[[Category:Nitrobenzodiazepines]]


{{nervous-system-drug-stub}}